Dolutegravir Based Regimens

  • Congress Data

    DTG/3TC: Barrier to Resistance

    Jan van Lunzen, Head of Translational Medical Research

    Post-CROI 2021 Webinar

    Andrew Zolopa, MD, VP, Head, North America Medical Affairs

    GEMINI 144 Week: Efficacy and Safety

    Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

    TANGO 96 Week: Efficacy and Safety

    Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

    GEMINI 48 Week: Adherence Analysis

    Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

    STAT 24 Week: Feasibility, Efficacy and Safety

    Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
  • Clinical Trials Data

    Post-CROI 2021 Webinar

    Andrew Zolopa, MD, VP, Head, North America Medical Affairs

    GEMINI 144 Week: Efficacy and Safety

    Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

    TANGO 96 Week: Efficacy and Safety

    Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

    GEMINI 48 Week: Adherence Analysis

    Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

    STAT 24 Week: Feasibility, Efficacy and Safety

    Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
  • Dosing

    Tivicay PD: An Option for Children Living with HIV

    Ana M. Puga, MD, Regional Medical Director
  • Pharmacokinetics

    Tivicay PD: An Option for Children Living with HIV

    Ana M. Puga, MD, Regional Medical Director
  • Safety

    Post-CROI 2021 Webinar

    Andrew Zolopa, MD, VP, Head, North America Medical Affairs

    Antiretroviral Therapy and Weight Gain

    Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
  • Virology/Resistance

    DTG/3TC: Barrier to Resistance

    Jan van Lunzen, Head of Translational Medical Research